Numab and Kaken Partner to Develop NM81 for IBD

Numab Therapeutics and Kaken Pharmaceutical have formed a partnership to develop NM81, a novel antibody that may become the first-ever treatment for inflammatory bowel disease.

Kaken has entered into a licensing agreement for NM81 in some Asian territories following a research partnership beginning in November 2024. Under the new agreement, Numab and Kaken will jointly advance NM81 through clinical proof of concept. Kaken will fund both preclinical and clinical development.

The agreement also includes financial terms tied to development. If products from this collaboration are successful, Kaken may receive payments from Numab reflecting its R&D investment in advancing NM81.

Also Read: NEXT Oncology Partners with Kansai Medical University

This partnership combines Numab Therapeutics’s expertise in multispecific antibodies with Kaken Pharmaceutical’s R&D and commercial capabilities in Asia, aiming to accelerate the development of new treatment options for IBD.